Title: Cortical disinhibition, noisy circuits, and schizophrenia: clinical and therapeutic implications.

**Abstract**

It is not yet clear how the molecular and cellular alterations identified in post-mortem tissue from individuals diagnosed with schizophrenia translate into the disabling symptoms and cognitive impairments associated with this disorder.

Approach: The purpose of this presentation is to present results from a series of fMRI and EEG studies evaluating healthy individuals, schizophrenia patients, and healthy individuals administered the NMDA-R antagonist, ketamine that have been analyzed and interpreted within the context of parallel studies employing biophysically-informed computational neuroscience models of the behavior of cortical microcircuits and macrocircuits.

Results: Three types of network disinhibiton are described: 1) gross disinhibition, "hyperactivity" that is associated with symptoms of psychosis, 2) disinhibition of the spatial dispersion of activation resulting in impairment in sparse coding of information, reduced memory precision, increased cortical signal variance "noise", and the emergence of "false" memories, and 3) disinhibition of suppressed inputs, resulting in pathological hyperconnectivity. We will show evidence that the progression of schizophrenia is associated with altered signal properties of cortical functional connectivity, potentially creating the opportunity for illness phase-specific pharmacotherapies for this disorder.
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